![](https://registration.pmi-live.com/wp-content/uploads/2022/05/Yourway-GD-reg-page-banner-1.png)
When the COVID-19 pandemic threatened to entirely disrupt clinical trials, decentralized clinical trials (DCT) and direct-to-patient (DTP) models were quickly adopted as a solution. DTP models present opportunities to increase patient convenience and engagement and to simplify recruitment and retention, particularly for rare diseases affecting small, geographically dispersed populations.